All In Biotech

Drug Trial Radar · NCT05570058

Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

A Multi-Cohort, Randomised, Placebo-Controlled Phase 2a Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Ascending Doses of RXC007 in Patients With Idiopathic Pulmonary Fibrosis

Last checked: Nov 19, 2026Latest source record: Aug 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

48

Actual

Start

Sep 8, 2022

Primary completion

Jun 25, 2024

Study completion Jan 9, 2025

Sponsor

Lead sponsor
Redx Pharma LtdIndustry
Sponsor type
Industry
Collaborators
Simbec-Orion Group
First posted
Oct 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the safety and tolerability of RXC007 when given for 12 weeks (84 days), alone and in combination with nintedanib or pirfenidone.

Conditions

  • IPF
  • Fibrosis

Interventions

  • RXC007Drug

    RXC007 will be administered in the form of oral capsules at 3 potential dose levels: 20 mg, 50mg and 70 mg in 5 cohorts. 12 patients of cohorts 1, 2 and the Expansion cohort will receive RXC007. The Dosage regimen is BID or QD.

  • PlaceboDrug

    The placebo will be administered in the form of oral capsules at each dose level to 4 of the 16 participants within cohorts 1, 2 and the Expansion cohort. The Dosage regimen is BID or QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of AEs and SAEs Changes in safety laboratory parameters, vital signs, and ECGsTime frame: From Day 1 to post-study follow up visit (12 weeks)
  2. Number of participants who report a change from normal range values for laboratory safety parameters (serum biochemistry, serum haematology or urinalysis) from first dose on Day 1 to post-study follow up visit.Time frame: From Day 1 to post-study follow up visit (12 weeks)
  3. Number of participants who report a change from normal range values for vital signs parameters (blood pressure, pulse rate, respiration rate, oral body temperature) from first dose on Day 1 to 12 weeks of treatmentTime frame: From Day 1 to post-study follow up visit (12 weeks)
  4. Number of participants who report a change from normal range values for any of the associated 12-Lead ECG parameters (heart rate, QT interval and QTcF interval) from first dose on Day 1 up to completion of the post-study visit.Time frame: From Day 1 to post-study follow up visit (12 weeks)

Locations

31 sites in 8 countries. Site status is shown where the registry gives one.

  • Medical University of Vienna

    Vienna, Austria

  • E PNE UZ Leuven

    Leuven, Belgium

  • CHU De Liège

    Liège, Belgium

  • Pneumologicka klinika 1.LF UK a

    Prague, Czechia

  • Azienda Ospedaliero-Universitaria "Ospedali-Riuniti" di Ancona

    Ancona, Italy

  • Azienda Ospedaliero Universitaria Policlinico ''G.Rodolico-San Marco''

    Catania, Italy

  • Colonello D'avanzo Hospital

    Foggia, Italy

  • PO Vito Fazzi

    Lecce, Italy

  • Ospedale S. Giuseppe Milano

    Milan, Italy

  • Azienda Ospedaliera Universitaria of Modena

    Modena, Italy

  • Fondazione Policlinico Universitario A. Gemelli

    Roma, Italy

  • Azienda Ospedaliera Universitaria Integrata Verona

    Verona, Italy

  • University Clinical Centre in Gdansk

    Gdansk, Poland

  • Barlicki University Hospital

    Lodz, Poland

  • Institute of Tuberculosis and Lung Diseases in Warsaw

    Warsaw, Poland

  • Policlinica Barcelona

    Barcelona, Spain

  • Hospital Universitario Clínic de Barcelona

    Barcelona, Spain

  • L'Hospital Universitari de Bellvitge

    Barcelona, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Hospital Universitario Central de Asturias

    Oviedo, Spain

  • Hospital Universitario Marqués de Valdecilla

    Santander, Spain

  • Hospital Clínico Universitario de Santiago de Compostela

    Santiago de Compostela, Spain

  • University Hospital of Geneve

    Geneva, Switzerland

  • Belfast City Hospital

    Belfast, United Kingdom

  • Queen Elizabeth Hospital

    Birmingham, United Kingdom

  • Royal Papworth Hospital NHSFT

    Cambridge, United Kingdom

  • Royal Infirmary of Edinburgh

    Edinburgh, United Kingdom

  • Guy's Hospital

    London, United Kingdom

  • Royal Brompton Hospital

    London, United Kingdom

  • Altnagelvin Area Hospital

    Londonderry, United Kingdom

  • Churchill Hospital, Oxford University Hospitals NHS Trust

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.